SEC Form 3: New insider Meswani Parag V claimed ownership of 33,733 shares
$SIOX
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 01/28/2022 |
3. Issuer Name and Ticker or Trading Symbol
Sio Gene Therapies Inc. [ SIOX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 33,733 | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (1) | 12/16/2028 | Common Stock | 15,625 | 9.2 | D | |
| Stock Option (Right to Buy) | (2) | 12/16/2028 | Common Stock | 15,625 | 9.2 | D | |
| Stock Option (Right to Buy) | (3) | 04/14/2029 | Common Stock | 20,875 | 8.48 | D | |
| Stock Option (Right to Buy) | (4) | 04/14/2029 | Common Stock | 12,500 | 8.48 | D | |
| Restricted Stock Units | (5) | (5) | Common Stock | 25,333 | (6) | D | |
| Stock Option (Right to Buy) | (7) | 10/04/2030 | Common Stock | 18,075 | 5.63 | D | |
| Restricted Stock Units | (8) | (8) | Common Stock | 8,033 | (6) | D | |
| Stock Option (Right to Buy) | (9) | 04/14/2031 | Common Stock | 219,000 | 2.47 | D | |
| Explanation of Responses: |
| 1. The option vested or vests, as applicable, over a period of four years with 25% of the shares of common stock underlying the option vested on November 26, 2019, and the remainder vested or vesting, as applicable, in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer through each such date. |
| 2. One-third of the option will vest at such time as the Issuer's 30-day trailing volume weighted average closing stock price ("30-day VWAP") is equal to $24.00; one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $40.00; and one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $56.00, in each case subject to the Reporting Person providing continuous service to the Issuer through each such date. |
| 3. The option vested or vests, as applicable, over a period of four years with 25% of the shares of common stock underlying the option vested on April 15, 2020, and the remainder vested or vesting, as applicable, in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer through each such date. |
| 4. One-third of the option will vest at such time as the Issuer's 30-day trailing volume weighted average closing stock price ("30-day VWAP") is equal to $16.96; one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $33.92; and one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $50.88, in each case subject to the Reporting Person providing continuous service to the Issuer through each such date. |
| 5. One-half of the restricted stock unit shall vest on April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. |
| 6. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. |
| 7. The option vested or vests, as applicable, over a period of four years with 25% of the shares of common stock underlying the option vested on October 5, 2021, and the remainder vested or vesting, as applicable, in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer through each such date. |
| 8. One-half of the restricted stock unit shall vest on October 5, 2022 and October 5, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. |
| 9. The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. |
| Remarks: |
| /s/ David Nassif, Attorney-in-Fact | 02/07/2022 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||